NFlection Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2014-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.nflectionrx.com
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
Phase 2
Completed
- Conditions
- Neurofibromatosis 1Cutaneous Neurofibroma
- Interventions
- Drug: NFX-179 gelDrug: Vehicle gel
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- NFlection Therapeutics, Inc.
- Target Recruit Count
- 199
- Registration Number
- NCT05005845
- Locations
- 🇺🇸
The Johns Hopkins School of Medicine, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Minnesota Clinical Study Center, New Brighton, Minnesota, United States
NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
Phase 2
Completed
- Conditions
- Neurofibromatosis 1Cutaneous Neurofibroma
- Interventions
- Drug: NFX-179 GelDrug: Vehicle Gel
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- NFlection Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04435665
- Locations
- 🇺🇸
Skin Search of Rochester, Inc., Rochester, New York, United States
🇺🇸Center for Dermatology Clinical Research, Inc., Fremont, California, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath